文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

复发性宫颈癌再程放疗:单中心经验

Re-irradiation for recurrent cervical cancer: A single institutional experience.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-10-10

本研究回顾性分析2015年1月至2017年12月在本院接受再程放疗的50例复发性宫颈癌患者的临床结局,所有患者接受容积旋转调强放疗(VMAT)或VMAT联合三维影像引导近距离放疗,并接受全身化疗。中位随访22个月,3年局部控制率、无进展生存率和总生存率分别为58.0%、38.7%和44.4%。作者认为再程放疗是部分患者有效且安全的挽救治疗选择。

要点

  • 再程放疗后3年局部控制率58.0%、无进展生存率38.7%、总生存率44.4%,中位无进展生存期14个月、总生存期26个月。
  • 两次放疗间隔超过12个月与更好的局部控制和无进展生存显著相关(p≤0.05),但总生存无显著获益(p>0.05)。
  • 血清鳞状细胞癌抗原(SCC-Ag)水平低于1.5 ng/ml对无进展生存有显著更好影响(p≤0.05)。

核心结论

  • 作者认为,采用VMAT的再程放疗是经选择患者中有效且安全的挽救治疗选择,具有尚可的临床结局和毒性特征。
  • 作者的经验中,两次放疗间隔超过12个月且血清SCC-Ag低于1.5 ng/ml的复发性宫颈癌患者结局更好。

研究设计与样本

  • 单中心回顾性分析,连续纳入2015年1月至2017年12月在本院接受再程放疗的所有患者。
  • 共纳入50例复发性宫颈癌患者,所有患者接受VMAT或VMAT后三维影像引导近距离放疗(3D-IGBT),并在再程放疗前后接受全身化疗。
  • 再程放疗的靶体积和剂量取决于既往放疗野、剂量学和复发部位。

主要发现

  • 从初次放疗到再程放疗的中位时间为12个月,中位随访22个月(范围4-59个月)。
  • 局部复发25例(50.0%),区域复发8例(16.0%),局部区域复发9例(18.0%),远处复发合并野内复发8例(16.0%)。
  • 3年局部控制率、无进展生存率和总生存率分别为58.0%、38.7%和44.4%;中位无进展生存期和总生存期分别为14个月和26个月。
  • 两次放疗间隔超过12个月与更好的局部控制和无进展生存显著相关(p≤0.05),但总生存无显著获益(p>0.05)。
  • 血清SCC-Ag水平低于1.5 ng/ml对无进展生存有显著更好影响(p≤0.05)。

关键数值与推荐

  • 再程放疗淋巴结剂量为45 Gy,伴或不伴推量至55-60 Gy;大体肿瘤剂量为36-45 Gy,伴或不伴推量至45-61 Gy。
  • 3年局部控制率58.0%、无进展生存率38.7%、总生存率44.4%。
  • 中位无进展生存期14个月,中位总生存期26个月。
  • 两次放疗间隔>12个月与更好局部控制和无进展生存相关(p≤0.05),总生存无显著获益(p>0.05)。
  • 血清SCC-Ag<1.5 ng/ml与更好无进展生存相关(p≤0.05)。

临床怎么用

  • 作者认为,再程放疗联合VMAT可作为经选择复发性宫颈癌患者的有效且安全的挽救治疗选择。
  • 作者的经验提示,两次放疗间隔超过12个月且血清SCC-Ag低于1.5 ng/ml的患者结局更好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Salvage treatment of recurrent cervical cancer of patients with a history of radiotherapy is currently a major clinical challenge. The purpose of our study was to retrospectively analyze clinical outcomes of radiation in patients with recurrent cancer who have previously received radiotherapy at our hospital and further explore the efficacy and safety of this treatment modality. METHODS: All consecutive patients who underwent re-irradiation were included in our department between January 2015 and December 2017. All the patients received Volumetric Modulated Arc Therapy (VMAT) alone or VMAT followed by three dimensional-image-guided brachytherapy (3D-IGBT). The volume and dose for re-irradiation depended on previous radiation fields, dosimetry and recurrence sites. All patients received systemic chemotherapy before or after re-irradiation. RESULTS: Fifty patients were included in our study. The median time from primary radiotherapy to re-irradiation was 12 months. Local recurrence, which was the most common failure following primary treatment, was present in 25 patients (50.0 %) while regional recurrence, loco-regional recurrence and distant recurrence combined in-filed recurrence was present in 8 (16.0 %), 9 (18.0 %) and 8 patients (16.0 %). Re-irradiation dose to lymph nodes was 45 Gy with or without a boost up to 55-60 Gy, and to the gross mass was 36-45 Gy with or without a boost up to 45-61 Gy. The median follow-up period was 22 (range,4-59) months. The 3-year local control (LC), progression-free survival (PFS), and overall survival (OS) rates were 58.0, 38.7, and 44.4 %, respectively. The median time of PFS and OS was 14 and 26 months, respectively. The interval between two successive radiotherapies beyond 12 months was significantly associated with better LC and PFS (p ≤ 0.05), but without the benefit of OS (p > 0.05). Serum SCC antigen level less than 1.5 ng/ml had a significantly better impact on PFS (p ≤ 0.05). Overall, 14 patients (28 %) experienced ≥ grade 3 acute toxicities, while 9 (18 %) experienced ≥ grade 3 late toxicities. CONCLUSIONS: Re-irradiation with VMAT is an effective and safe salvage treatment option with a reasonably good clinical outcome and toxicity profile in selected patients. In our experience, recurrent cancer patients with an interval between two successive radiotherapy courses beyond 12 months and with a serum SCC-Ag level less than 1.5 ng/ml, had improved outcomes.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Li J, Huang L, Wu H, et al. Re-irradiation for recurrent cervical cancer: A single institutional experience. Clin Transl Radiat Oncol. 2023. PMID: 37876912. doi:10.1016/j.ctro.2023.100690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。